GROWTH-INHIBITION OF A COLONIC ADENOCARCINOMA CELL-LINE (HT29) BY T-CELLS SPECIFIC FOR MUTANT P21 RAS

被引:14
作者
GEDDEDAHL, T
NILSEN, E
THORSBY, E
GAUDERNACK, G
机构
[1] UNIV OSLO,N-0027 OSLO,NORWAY
[2] NATL HOSP NORWAY,INST PATHOL,IMMUNOHISTOCHEM & IMMUNOPATHOL LAB,N-0027 OSLO,NORWAY
关键词
RAS; ONCOGENE; T CELLS; IMMUNOTHERAPY;
D O I
10.1007/BF01526208
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations at codons 12, 13 or 61 of the ras proto-oncogenes are found in adenocarcinomas of the colon and rectum. Mutated ras encode tumor-specific proteins, and can elicit CD4(+) HLA-class-II-restricted T cell responses both in mouse and man. The function of such T cells is, however, unclear. In a model system, we investigated whether HLA-class-II restricted CD4(+) T cells, specific for a particular peptide derived from mutant p21 ras (Gln(61) -> Leu), might inhibit the growth of a colonic cancer cell line, when it was cultured in the presence of the corresponding peptide. We found in this case that the growth of the colonic adenocarcinoma cell line HT29, when also induced to express HLA class II molecules by interferon gamma treatment, was inhibited. The inhibition was peptide-specific and required the presence of HLA-DQ8 molecules on the target cell. However, HLA-DQ8-expressing HT29 cells functioned poorly as antigen-presenting cells and could only induce a weak proliferative T cell response in the presence of interleukin-2. The results suggest that colonic cancer cells expressing peptides derived from mutant p21 ras protein in a complex with HLA class II molecules may be a target for tumor-specific T cells. The results also indicate, however, that an initiation of the immune response will require ''professional'' antigen-presenting cells.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 41 条
[1]  
ANZANO MA, 1989, CANCER RES, V49, P2898
[2]  
BETTERLE C, 1991, CANCER, V67, P977, DOI 10.1002/1097-0142(19910215)67:4<977::AID-CNCR2820670420>3.0.CO
[3]  
2-W
[4]   IDIOTOPE-SPECIFIC T-CELL CLONES THAT RECOGNIZE SYNGENEIC IMMUNOGLOBULIN FRAGMENTS IN THE CONTEXT OF CLASS-II MOLECULES [J].
BOGEN, B ;
MALISSEN, B ;
HAAS, W .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1986, 16 (11) :1373-1378
[5]   PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].
BOS, JL ;
FEARON, ER ;
HAMILTON, SR ;
VERLAANDEVRIES, M ;
VANBOOM, JH ;
VANDEREB, AJ ;
VOGELSTEIN, B .
NATURE, 1987, 327 (6120) :293-297
[6]   COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4 [J].
CHEN, LP ;
ASHE, S ;
BRADY, WA ;
HELLSTROM, I ;
HELLSTROM, KE ;
LEDBETTER, JA ;
MCGOWAN, P ;
LINSLEY, PS .
CELL, 1992, 71 (07) :1093-1102
[7]   SPECIFICITY AND PROMISCUITY AMONG NATURALLY PROCESSED PEPTIDES BOUND TO HLA-DR ALLELES [J].
CHICZ, RM ;
URBAN, RG ;
GORGA, JC ;
VIGNALI, DAA ;
LANE, WS ;
STROMINGER, JL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (01) :27-47
[8]   THE DETAILED DISTRIBUTION OF HLA-A-ANTIGEN, B-ANTIGEN, C-ANTIGEN IN NORMAL HUMAN ORGANS [J].
DAAR, AS ;
FUGGLE, SV ;
FABRE, JW ;
TING, A ;
MORRIS, PJ .
TRANSPLANTATION, 1984, 38 (03) :287-292
[9]  
DEEM RL, 1991, CLIN EXP IMMUNOL, V83, P79
[10]  
EBERT EC, 1987, J IMMUNOL, V138, P2161